20 Oct

Biogen Stock: Performance in 3Q17

WRITTEN BY Mike Benson

A look at Biogen

Headquartered in Cambridge, Massachusetts, Biogen (BIIB) is a biopharmaceutical company. It discovers, develops, and manufactures drugs for various therapeutic areas, including immunology, neurology, oncology, and rare diseases.

Biogen Stock: Performance in 3Q17

The above chart shows revenues and EPS (earnings per share) over the last eight quarters and estimates for 3Q17.

Stock performance

Biogen stock has risen ~15.4% in 3Q17, while it has risen ~31.1% year-to-date as of October 20, 2017.

Analyst recommendations

Wall Street analysts estimate that the stock has the potential to rise ~1.0% over the next 12 months. Their recommendations show a 12-month target price of $345.79 per share compared to the last price of $342.42 per share as of October 19, 2017.

There are 29 analysts tracking Biogen stock. Twenty of them recommend a “buy,” and nine recommend a “hold.” None of them have recommended a “sell.” The consensus rating for Biogen stands at 2.07, which represents a “strong buy” for long-term growth investors and a “moderate buy” for momentum investors.

Analysts’ revenue estimates

Biogen’s revenues are mainly driven by strong sales of its neurology products as well as its immuno-oncology products.

Wall Street analysts estimate revenues of $3.0 billion in 3Q17, a ~2.8% rise compared to 3Q16, and EPS of $5.73.

To divest the company-specific risks, investors can consider ETFs such as the Health Care Select Sector SPDR ETF (XLV), which holds 2.2% of its total assets in Biogen (BIIB). XLV also holds 3.2% in Bristol-Myers Squibb (BMY), 2.5% in Eli Lilly (LLY), and 2.4% in Abbott Laboratories (ABT).

Latest articles

McDonald’s (MCD) competition includes large international and national food chains as well as regional and local retailers of food products.

The restaurant industry is susceptible to a wide array of risks of macro and micro factors. As a huge global brand, McDonald’s faces several risks.

Google plans to offer a smart checking account along with Citigroup and Stanford Federal Credit Union. Tentatively called Cache, it could launch in 2020.

The proposed T-Mobile-Sprint merger agreement expired on November 1. Either company has the right to walk away from the transaction until a new date is set.

Since my last article about Nvidia (NVDA), the stock has risen from $196.86 to $208.57. I expect a further rise after today's earnings results.

TJX Companies (TJX) is scheduled to announce its fiscal 2020 third-quarter earnings results on November 19. Its third quarter ended on November 2.